Transcriptome sequencing in prostate cancer identifies inter-tumor heterogeneity.

Area of Science:

• Oncology
• Genomics
• Cancer Biology

Background:

• Prostate cancer evolution is poorly understood, with few known gene mutations.
• Genomic rearrangements are hypothesized to be significant drivers of prostate cancer.
• Individualized tumor alterations, or "private alterations," are understudied but may offer unique insights.

Purpose of the Study:

• To identify unique genomic alterations in high-risk prostate cancer with a lethal phenotype.
• To investigate the role of these alterations in tumor evolution and clinical outcome.
• To explore potential therapeutic targets based on individual tumor alterations.

Main Methods:

• Transcriptome sequencing was employed to analyze a cohort of high-risk prostate cancer patients.
• High-throughput sequencing data was used to identify genomic rearrangements and gene fusions.
• Bioinformatic analysis was performed to categorize altered genes into cancer-relevant pathways.

Main Results:

• Significant inter-tumor heterogeneity was observed in the patient cohort.
• Despite heterogeneity, altered genes converged into three key cancer-relevant pathways.
• Several non-ETS gene fusions were identified as potentially contributing to tumor phenotype and progression.

Conclusions:

• Unique genomic alterations, including non-ETS fusions, are present in high-risk prostate cancer.
• These alterations contribute to the diverse phenotypes and progression of individual tumors.
• Understanding these private alterations is vital for personalized treatment strategies in prostate cancer.